The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study*
Abstract
Aim: The aim of this study was to compare the efficacy and tolerability of vildagliptin vs. pioglitazone as add‐on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Methods: This 24‐week, multicentre, double‐blind, randomized, active‐controlled study compared vildagliptin (100 mg daily, given as equally divided doses, n = 295) and pioglitazone (30 mg daily, given as a single q.d. dose, n = 281) in patients with inadequate glycaemic control (A1C 7.5–11%) while receiving a stable metformin dose (≥1500 mg daily). The adjusted mean changes from baseline to study endpoint (AMΔ) in A1C, fasting plasma glucose (FPG), fasting lipids and body weight were compared by analysis of covariance. Results: When added to a stable dose of metformin (mean dose at baseline >2000 mg/day), both vildagliptin and pioglitazone decreased A1C (AMΔ = −0.9 ± 0.1% and −1.0 ± 0.1%, respectively) from identical baseline values (8.4 ± 0.1%). The between‐group difference in AMΔ A1C was 0.1 ± 0.1%, and non‐inferiority of vildagliptin to pioglitazone was established at both 0.4 and 0.3% margins for upper limit of the 95% confidence intervals. Pioglitazone decreased FPG (AMΔ = −2.1 ± 0.1 mmol/l) to a greater extent than vildagliptin (AMΔ = −1.4 ± 0.1 mmol/l), but only pioglitazone increased body weight (AMΔ = +1.9 ± 0.2 kg: between‐group difference = −1.6 ± 0.3 kg, p < 0.001). Adverse events (AEs) were reported by 60% of vildagliptin‐treated patients and by 56.4% of pioglitazone‐treated patients; serious AEs were reported by 2.0 and 4.6% of patients receiving vildagliptin and pioglitazone respectively. Mild hypoglycaemia was reported by one patient (0.3%) in the vildagliptin group and by no patients receiving pioglitazone. Conclusions: When added to metformin, the efficacy of vildagliptin is non‐inferior to that of pioglitazone. The treatments were similarly well tolerated, but only pioglitazone increased body weight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
Charbonnel, B., Schernthaner, G., Brunetti, P., Matthews, D. R., Urquhart, R., Tan, M. H., & Hanefeld, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1751-1 · Cited by 170
Cited by
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Metformin: clinical use in type 2 diabetes
Sanchez-Rangel, E., & Inzucchi, S. E. (2017) · Diabetologia · doi:10.1007/s00125-017-4336-x · Cited by 595
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435
Metadata
- Authors
- Bolli, G., Dotta, F., Rochotte, E., & Cohen, S. E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2007-11-22
- Volume
- 10
- Issue
- 1
- Pages
- 82-90
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2079787842
- Cited by
- 192
- References
- 4
- FWCI
- 17.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study*. https://app.cochat.ai/papers/10.1111/j.1463-1326.2007.00820.x
- The paper
- Bolli, G., Dotta, F., Rochotte, E., & Cohen, S. E. (2008). Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study*. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2007.00820.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.